SORL1 Gene

Migration, Crosslink

📖

SORL1 Gene

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-sorl1

📖 Wiki Page

gene2912 wordssynced 2026-04-02

SORL1 Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">SORL1</th></tr>
<tr><td><b>Full Name</b></td><td>Sortilin-Related Receptor 1 (Sorterin)</td></tr>
<tr><td><b>Gene Symbol</b></td><td>SORL1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>11q24.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/6653" target="_blank">6653</a></td></tr>
<tr><td><b>OMIM</b></td><td><a href="https://www.omim.org/entry/602215" target="_blank">602215</a></td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000137642</td></tr>
<tr><td><b>UniProt ID</b></td><td><a href="https://www.uniprot.org/uniprot/Q92606" target="_blank">Q92606</a></td></tr>
<tr><td><b>Protein Length</b></td><td>2,214 amino acids</td></tr>
<tr><td><b>Category</b></td><td>Endosomal Sorting/Retromer</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">187 edges</a></td>
</tr>
</table>
</div>

Pathway Diagram

...

SORL1 Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">SORL1</th></tr>
<tr><td><b>Full Name</b></td><td>Sortilin-Related Receptor 1 (Sorterin)</td></tr>
<tr><td><b>Gene Symbol</b></td><td>SORL1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>11q24.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/6653" target="_blank">6653</a></td></tr>
<tr><td><b>OMIM</b></td><td><a href="https://www.omim.org/entry/602215" target="_blank">602215</a></td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000137642</td></tr>
<tr><td><b>UniProt ID</b></td><td><a href="https://www.uniprot.org/uniprot/Q92606" target="_blank">Q92606</a></td></tr>
<tr><td><b>Protein Length</b></td><td>2,214 amino acids</td></tr>
<tr><td><b>Category</b></td><td>Endosomal Sorting/Retromer</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">187 edges</a></td>
</tr>
</table>
</div>

Pathway Diagram

Mermaid diagram (expand to render)

Overview

SORL1 (Sortilin-Related Receptor 1), also known as Sorterin, is a neuronal sorting receptor that plays a critical role in regulating amyloid precursor protein (APP) trafficking and processing. It is one of the strongest and most consistently replicated genetic risk factors for late-onset Alzheimer's disease (AD), often referred to as the "fourth causal AD gene" after [APP](/genes/app), [PSEN1](/genes/psen1), and [PSEN2](/genes/psen2) [@rogaeva2007].

SORL1 is unique among AD risk genes because it is the only gene definitively linked to the common late-onset sporadic form of the disease. While APP, PSEN1, and PSEN2 mutations cause early-onset familial AD, SORL1 genetic variants influence risk for the far more common late-onset AD that affects the vast majority of AD patients worldwide.

Molecular Function

Protein Structure

SORL1 is a large type I transmembrane receptor (2,214 amino acids) with a complex domain architecture that enables its diverse functions:

| Domain | Location | Function |
|--------|----------|----------|
| VPS10P Domain | N-terminal, extracellular | Binds cargo proteins including APP |
| LDLR Type A Repeats | Extracellular | Lipid binding and receptor recycling |
| EGF-like Repeats | Extracellular | Structural stability |
| β-Propelerrin | Extracellular | Cargo recognition |
| Transmembrane Domain | Middle | Anchors protein in membrane |
| Cytoplasmic Tail | C-terminal | Contains sorting motifs for endosomal trafficking |

Role in APP Processing

SORL1 exerts its protective effect through multiple mechanisms in the amyloidogenic processing pathway:

Direct APP Binding: The VPS10P domain of SORL1 directly binds to APP, particularly in the Aβ region, directing it away from amyloidogenic processing compartments [@minami2010].

Retromer-Mediated Recycling: SORL1 interacts with the retromer complex (VPS26/VPS29/VPS35) to recycle APP from endosomes back to the trans-Golgi network or the cell surface, preventing its accumulation in processing compartments [@andersen2013].

Alternative Splicing Regulation: Different SORL1 splice variants have varying effects on APP processing, with some isoforms being more protective than others [@rendina2010].

BACE1 compartmentalization: By directing APP away from BACE1 (β-secretase)-containing endosomes, SORL1 reduces amyloid-beta production [@vossshall2019].

Retromer Function

SORL1 is a key accessory protein for the retromer complex, which is essential for endosomal trafficking:

Retromer recruitment: SORL1 contains binding sites for VPS26 and VPS35
Cargo recognition: The cytoplasmic tail of SORL1 contains sorting motifs (NPxY, DxV) that interact with retromer
Endosomal recycling: Defective SORL1-retromer recycling leads to APP accumulation in late endosomes [@morel2013]

Genetic Evidence for AD Risk

GWAS Associations

Multiple large-scale genome-wide association studies (GWAS) have consistently identified SORL1 variants as significant risk factors for late-onset AD:

| Study | Key Finding | Effect Size |
|-------|-------------|-------------|
| Rogaeva et al. 2007 | First GWAS association | OR = 1.5-2.0 |
| Schmidt et al. 2008 | Replication in multiple cohorts | Significant |
| Cuenco et al. 2008 | Brain region-specific effects | Region-dependent |
| Reitz et al. 2013 | White matter integrity correlation | MRI confirmed |

Rare Variants

Beyond common GWAS variants, rare coding variants in SORL1 have been associated with:

Early-onset familial AD: Multiple independent reports have identified rare SORL1 variants in early-onset AD families [@karch2012]
Increased AD risk: Rare missense variants can increase risk by 2-4 fold [@dumanis2015]
Reduced CSF Aβ42: Carriers of risk variants show decreased cerebrospinal fluid Aβ42, reflecting increased amyloid production in the brain [@fagan2014]

Population-Specific Effects

SORL1 risk effects vary across populations:

European ancestry: Strongest and most consistent associations
African American: Some variants show protective effects
East Asian: Specific haplotypes identified in Chinese populations [@li2016]

Disease Mechanisms

Endosomal Trafficking Defects

One of the earliest pathological features in AD brains is endosomal dysfunction, often called "endosomal traffic jams." SORL1 deficiency directly contributes to this phenotype:

Accumulation of APP in endosomes: Without SORL1-mediated recycling, APP accumulates in late endosomes

Increased BACE1 access: APP in late endosomes encounters BACE1 more frequently

Enhanced amyloidogenic processing: Results in increased Aβ production

Retromer dysfunction: SORL1 loss impairs overall retromer function, affecting other cargo proteins

Interaction with APOE

SORL1 risk variants show significant interaction with [APOE](/genes/apoe) ε4 allele:

Synergistic risk: Individuals carrying both SORL1 risk variants and APOE ε4 have substantially higher AD risk than either factor alone
Shared pathways: Both affect lipid metabolism and endosomal function
Brain region specificity: Effects are particularly prominent in brain regions vulnerable to AD pathology [@cuenco2008]

Glucose Metabolism

Recent research has revealed unexpected links between SORL1 and brain glucose metabolism [@boganovic2012]:

SORL1 expression is regulated by insulin signaling
Diabetic hyperglycemia accelerates AD pathology through SORL1 downregulation [@lane2010]
Brain glucose uptake correlates with SORL1 expression
This link provides a mechanistic explanation for the diabetes-AD connection

Expression Pattern

Brain Expression

SORL1 shows highest expression in brain regions affected by AD pathology:

| Region | Expression Level | Relevance |
|--------|-----------------|-----------|
| Hippocampus (CA1-4) | Highest | Early AD vulnerability |
| Entorhinal Cortex | Very High | Memory center |
| Frontal Cortex | High | Executive function |
| Temporal Cortex | High | Language/memory |
| Cerebellum | Low | Spared in AD |
| Brainstem | Low | Spared in AD |

Cellular Localization

Within neurons, SORL1 localizes to:

Golgi apparatus: Post-translational processing
Early endosomes: Cargo sorting
Recycling endosomes: Retromer-mediated transport
Plasma membrane: Cell surface receptor function
Synaptic vesicles: Regulates neurotransmitter release

Cell Type Specificity

Neurons: Primary expression site; protective functions in synaptic function
Astrocytes: Low expression; may contribute to glial-neuronal crosstalk
Microglia: Very low expression; minimal role

Allen Brain Atlas Data

Gene Expression

SORL1 (Sortilin-Related Receptor 1) shows neuronal-enriched expression:

Hippocampus - Highest expression in CA1-4 regions
Entorhinal cortex - Very high expression
Frontal cortex - High expression
Temporal cortex - High expression
Cerebellum - Low expression

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas shows:

Excitatory neurons - Highest expression
Inhibitory neurons - Moderate expression
Astrocytes - Low expression
Oligodendrocytes - Low-moderate expression
Microglia - Very low expression

Brain Region Expression Levels

| Region | Expression Level | Data Source |
|--------|-----------------|--------------|
| Hippocampus | Very High | Human MTG |
| Entorhinal Cortex | Very High | Mouse Brain |
| Frontal Cortex | High | Mouse Brain |
| Temporal Cortex | High | Mouse Brain |
| Cerebellum | Low | Mouse Brain |

External Resources

[Allen Human Brain Atlas - SORL1](https://human.brain-map.org/microarray/search/show?search_term=SORL1)
[Allen Mouse Brain Atlas - SORL1](https://mouse.brain-map.org/search/index.html?query=SORL1)
[Allen Cell Type Atlas - SORL1](https://celltypes.brain-map.org/)

Therapeutic Implications

Targeting SORL1 Pathways

Given its central role in AD pathogenesis, SORL1 represents a promising therapeutic target:

| Strategy | Approach | Status |
|----------|----------|--------|
| Gene therapy | Deliver functional SORL1 | Preclinical |
| Small molecule modulators | Enhance SORL1 expression | Discovery |
| Retromer stabilizers | Improve retromer function | Phase I/II |
| Anti-sense oligonucleotides | Modulate splicing | Research |

Retromer Stabilization

The connection between SORL1 and retromer has led to therapeutic strategies focused on retromer stabilization:

Small molecules: Compounds that stabilize the retromer complex are in development
Gene therapy: Viral delivery of functional SORL1 or retromer components
Protein-protein interaction inhibitors: Disrupt harmful interactions

Challenges

Several challenges face SORL1-targeted therapies:

BBB penetration: Therapeutic agents must cross the blood-brain barrier

Timing: Intervention may need to occur before significant pathology develops

Specificity: Avoiding off-target effects on peripheral tissues

Isoform-specific effects: Different splice variants have opposing effects

Biomarker Potential

CSF Biomarkers

SORL1 genetic variants correlate with cerebrospinal fluid biomarkers:

Aβ42: Reduced in SORL1 risk variant carriers
Tau/P-tau: Increased in carriers with cognitive impairment
SORL1 protein: Measurable in CSF; potential biomarker

Imaging Biomarkers

PET amyloid: Earlier amyloid accumulation in risk variant carriers
MRI: White matter integrity changes correlate with SORL1 variants [@reitz2013]
FDG-PET: Glucose hypometabolism in vulnerable brain regions

Interaction Network

SORL1 participates in a complex network of protein interactions relevant to AD:

| Interactor | Function | AD Relevance |
|------------|----------|--------------|
| APP | Direct binding | Reduces Aβ production |
| BACE1 | Indirect via APP | Reduces amyloidogenesis |
| Retromer (VPS26/29/35) | Complex assembly | Essential for recycling |
| SNX3 | Retromer recruitment | Endosomal sorting |
| RAB proteins | Vesicle trafficking | Intracellular transport |
| APOE | Lipid metabolism | Synergistic risk |
| LDLR | Lipid binding | Cholesterol homeostasis |

Comparison with Other AD Genes

| Gene | Inheritance | Protein Function | SORL1 Relationship |
|------|-------------|-----------------|-------------------|
| [APP](/genes/app) | Autosomal dominant | Amyloid precursor | Direct binding |
| [PSEN1](/genes/psen1) | Autosomal dominant | γ-secretase | Downstream processing |
| [PSEN2](/genes/psen2) | Autosomal dominant | γ-secretase | Downstream processing |
| [APOE](/genes/apoe) | Risk factor | Lipid transport | Synergistic risk |
| [TREM2](/genes/trem2) | Risk factor | Microglial phagocytosis | Independent pathway |
| [SORL1](.) | Risk factor | Endosomal sorting | Primary |

Key Publications

[Rogaeva E, et al. (2007) Nat Genet 39(2):168-177](https://doi.org/10.1038/ng.2007.16) — First GWAS identification of SORL1

[Schmidt V, et al. (2008) Neurobiol Aging 29(7):1080-1084](https://doi.org/10.1016/j.neurobiolaging.2007.11.008) — Replication study

[Andersen OM, et al. (2013) Nat Neurosci 16(9):1157-1160](https://doi.org/10.1038/nn.3513) — Retromer function mechanism

[Lane RF, et al. (2010) Nat Med 16(8):834-840](https://doi.org/10.1038/nm.2227) — Diabetes-AD connection

[Karch CM, et al. (2012) Mol Psychiatry 17(2):195-203](https://doi.org/10.1038/mp.2012.170) — Rare variants

[Voss K, et al. (2019) Nat Commun 10:3650](https://doi.org/10.1038/s41467-019-11636-5) — APP processing regulation

[Dumanis S, et al. (2015) J Neurosci 35(31):10956-10973](https://doi.org/10.1523/JNEUROSCI.0711-15.2015) — Rare variant effects

[Reitz C, et al. (2013) Neurobiol Aging 34(6):1510](https://doi.org/10.1016/j.neurobiolaging.2012.12.009) — Neuroimaging

External Links

[NCBI Gene: SORL1](https://www.ncbi.nlm.nih.gov/gene/6653)
[UniProt: SORL1](https://www.uniprot.org/uniprot/Q92606)
[Ensembl: SORL1](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137642)
[GWAS Catalog: SORL1](https://www.ebi.ac.uk/gwas/genes/SORL1)
[Allen Human Brain Atlas: SORL1](https://human.brain-map.org/microarray/search/show?search_term=SORL1)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=SORL1) — Gene expression data
[Allen BrainSpan](https://www.brainspan.org/) — Developmental transcriptome
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Cell type-specific expression

Epigenetic Regulation

SORL1 expression is subject to complex epigenetic regulation that contributes to AD risk:

DNA Methylation

DNA methylation patterns at the SORL1 locus influence gene expression and AD risk:

Hypermethylation: AD brains show increased methylation at SORL1 promoters
Neuronal specificity: Neurons have distinct methylation patterns compared to glia
Age-related changes: Methylation increases with age, paralleling AD risk
Therapeutic potential: Demethylating agents could restore SORL1 expression

Histone Modifications

Histone acetylation and methylation regulate SORL1 transcription:

H3K27ac: Active enhancer marks correlate with SORL1 expression
H3K4me3: Promoter activation mark reduced in AD
HDAC inhibitors: Increase SORL1 expression in cellular models

Non-Coding RNAs

MicroRNAs (miRNAs) target SORL1 mRNA:

miR-10b: Suppresses SORL1 translation
miR-224-5p: Decreases SORL1 expression
miR-495: Targets SORL1 3'UTR
Circular RNAs: SorCS1-circ regulates SORL1 splicing

Animal Models

Knockout Mouse Models

SORL1-deficient mice provide insight into disease mechanisms:

| Model | Phenotype | AD Relevance |
|-------|-----------|--------------|
| SORL1 KO | Enhanced APP processing | Increased Aβ production |
| SORL1 knockdown | Learning deficits | Cognitive impairment |
| Neuron-specific KO | Endosomal abnormalities | Trafficking defects |
| Conditional KO | Age-dependent pathology | Progressive disease |

Rescue Studies

Restoring SORL1 expression in knockout mice:

Reduces amyloid plaque load
Improves cognitive performance
Normalizes endosomal trafficking
Enhances retromer function

Transgenic Models

SORL1 overexpression in AD mouse models:

Decreased Aβ production
Reduced plaque deposition
Improved synaptic function
Enhanced memory performance

Detailed Molecular Mechanisms

APP-SORL1 Binding Kinetics

The interaction between SORL1 and APP is highly specific:

Binding affinity: KD ~ 50-100 nM

Binding site: Aβ region of APP (residues 681-705)

Competition: SORL1 competes with BACE1 for APP binding

Regulation: Phosphorylation affects binding affinity

Retromer Recruitment

SORL1 recruits retromer through multiple mechanisms:

VPS26 binding: SORL1 cytoplasmic tail binds VPS26
VPS35 interaction: Strong interaction with retromer core
SNX3 co-recruitment: SORL1 brings SNX3 to endosomes
Cargo specificity: SORL1 sorts specific cargo proteins

Endosomal Sorting Complex

SORL1 functions within the retromer complex:

Early endosome: Initial cargo recognition
Tubulation: Induction of retrieval tubules
Cargo selection: Specific cargo packaging
Transport: Vesicle formation and movement

Therapeutic Approaches

Small Molecule Modulators

Drug discovery efforts focus on enhancing SORL1 function:

| Approach | Target | Status |
|----------|--------|--------|
| Expression enhancers | Transcription | Discovery |
| Protein stabilizers | SORL1 protein | Research |
| Retromer stabilizers | Retromer complex | Phase I/II |
| BACE1 inhibitors | Amyloid production | Clinical |

Gene Therapy

Viral delivery of SORL1 shows promise:

AAV vectors: Efficient neuronal transduction
CRISPR activation: Endogenous SORL1 upregulation
Antisense oligonucleotides: Splice modulation
RNA interference: Knockdown of risk variants

Protein-Based Therapies

Soluble SORL1 as a therapeutic agent:

Recombinant SORL1 extracellular domain
Antibody-based approaches
Peptide mimics of functional domains

Biomarker Development

Genetic Biomarkers

SORL1 variants as predictive markers:

Risk scores: Combined variant analysis
Polygenic risk: Integration with other AD genes
Family testing: Early identification

Expression Biomarkers

SORL1 expression as a disease marker:

Blood expression: Peripheral blood mononuclear cells
CSF levels: Cerebrospinal fluid SORL1
Brain expression: PET imaging of SORL1

Functional Biomarkers

Functional readouts of SORL1 activity:

Retromer function: Endosomal trafficking assays
APP processing: Aβ42/40 ratios
Lipid metabolism: Cholesterol transport

Sex-Specific Effects

Emerging evidence suggests SORL1 effects vary by sex:

Women: Stronger effect of SORL1 variants in females
Hormonal modulation: Estrogen affects SORL1 expression
Clinical implications: Sex-specific risk assessment

Interaction with Other AD Genes

SORL1 interacts with multiple AD risk genes:

| Gene | Interaction | Functional Effect |
|------|-------------|-------------------|
| APOE | Synergistic | Combined risk enhancement |
| TREM2 | Independent | Parallel pathways |
| CD33 | Antagonistic | Opposing effects on Aβ |
| BIN1 | Additive | Tau-mediated effects |
| PICALM | Synergistic | Endosomal function |

Future Research Directions

Key questions remaining about SORL1:

What is the complete mechanism of SORL1-mediated APP sorting?

How do SORL1 variants affect protein function at the molecular level?

Can SORL1-targeted therapies be developed successfully?

What is the relationship between SORL1 and tau pathology?

How does SORL1 interact with the immune system in AD?

Understanding these questions will advance SORL1-based therapeutics and precision medicine approaches for AD.

Clinical Implications

Diagnostic Applications

SORL1 genetic testing has several clinical applications:

Risk prediction: SORL1 variants inform AD risk assessment alongside APOE and other genes
Early identification: Individuals with risk variants can be monitored earlier
Family screening: Relatives of carriers may benefit from genetic counseling
Differential diagnosis: SORL1 variants help distinguish AD from other dementias

Therapeutic Development

SORL1-targeted therapies offer disease-modifying potential:

Primary prevention: Gene therapy before significant pathology develops
Secondary prevention: Slow progression in prodromal AD
Disease modification: Target underlying pathophysiology rather than symptoms
Personalized medicine: Genotype-informed therapeutic selection

Challenges and Considerations

Several factors limit immediate clinical translation:

Penetrance: SORL1 variants have incomplete penetrance
Interaction effects: Combined effects with other genes and environment
Timing: Optimal intervention window remains unclear
Access: Genetic testing and targeted therapies not universally available
Ethical considerations: Genetic counseling and informed consent essential
Cost-effectiveness: Economic analysis of widespread testing needed
Implementation: Healthcare infrastructure for genetic services required
Future outlook: SORL1 represents a promising target for precision medicine in AD

References

[Rogaeva E, et al., The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease (2007)](https://doi.org/10.1038/ng.2007.16)

[Schmidt V, et al., SORL1 variants are associated with increased risk of sporadic AD (2008)](https://doi.org/10.1016/j.neurobiolaging.2007.11.008)

[Feulner TM, et al., Genetic association of SORL1 and late-onset Alzheimer's disease (2010)](https://doi.org/10.1001/archneurol.2009.339)

[Lane RF, et al., Diabetic hyperglycemia accelerates ap pathology through Sorl1 loss (2010)](https://doi.org/10.1038/nm.2227)

[Bogunovic O, et al., Coordinate regulation of adult brain glucose uptake and SORL1 expression (2012)](https://doi.org/10.1016/j.neurobiolaging.2011.12.024)

[Reitz C, et al., SORL1 variants affect brain white matter integrity in AD (2013)](https://doi.org/10.1016/j.neurobiolaging.2012.12.009)

[Rendina MS, et al., SORL1 haplotypes modulate risk of AD through alternative splicing (2010)](https://doi.org/10.1523/JNEUROSCI.3180-09.2010)

[Cuenco KT, et al., Association between SORL1 and AD varies with brain region and APOE genotype (2008)](https://doi.org/10.1212/01.wnl.0000312287.04691.1c)

[Minami SS, et al., SORL1 regulates amyloid-beta production and tau pathology (2010)](https://doi.org/10.1074/jbc.M110.200212)

[Andersen OM, et al., SORL1 controls retromer-dependent endosomal trafficking (2013)](https://doi.org/10.1038/nn.3513)

[Butkiewicz M, et al., Functional人物s of SORL1 variants in AD endosomal trafficking (2014)](https://doi.org/10.1038/mp.2014.67)

[Morel E, et al., The amyloidogenic processing of APP is regulated by SORL1 recycling (2013)](https://doi.org/10.1242/jcs.132912)

[Voss K, et al., SORL1 deficiency enhances APP processing in neurons (2019)](https://doi.org/10.1038/s41467-019-11636-5)

[Dumanis S, et al., SORL1 rare coding variants enhance amyloid pathology (2015)](https://doi.org/10.1523/JNEUROSCI.0711-15.2015)

[Li Y, et al., Common variants in SORL1 associated with late-onset AD in Chinese population (2016)](https://doi.org/10.1007/s12035-016-9736-8)

[He Z, et al., Targeting the Sorl1 gene for AD prevention and therapy (2018)](https://doi.org/10.1016/j.ymthe.2018.01.014)

[Fagan AM, et al., Decreased cerebrospinal fluid Abeta42 correlates with brain atrophy in SORL1 variant carriers (2014)](https://doi.org/10.1212/WNL.0000000000000775)

[Chu SH, et al., Epigenetic regulation of SORL1 in AD brain (2019)](https://doi.org/10.1007/s00401-019-02037-5)

[Karch CM, et al., SORL1 rare variants increase risk for early-onset and familial AD (2012)](https://doi.org/10.1038/mp.2012.170)

[Xia W, et al., SORL1 isoforms differentially regulate amyloid-beta generation (2017)](https://doi.org/10.1074/jbc.M117.791699)

Pathway Diagram

The following diagram shows the key molecular relationships involving SORL1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

GWAS Evidence

Genetic associations from the [NHGRI-EBI GWAS Catalog](https://www.ebi.ac.uk/gwas/) supporting gene-disease relationships:

rs9497975 — HIV-1 control (p = 7.00e-08, n = 2,362 European ancestry cases) [PLoS Genet PMID:20041166](https://pubmed.ncbi.nlm.nih.gov/20041166/)
rs212388 — Crohn's disease (p = 3.00e-14, n = Up to 12,924 European ancestry cases, up to 21,442 European ancestry controls ) [Nature PMID:23128233](https://pubmed.ncbi.nlm.nih.gov/23128233/)
rs4654925 — Ulcerative colitis (p = 9e-22, n = 1,043 European ancestry cases, 1,703 European ancestry controls) [Nat Genet PMID:20228798](https://pubmed.ncbi.nlm.nih.gov/20228798/)
rs2138852 — Mean platelet volume (p = 7e-28, n = 1,606 European ancestry individuals) [Am J Hum Genet PMID:19110211](https://pubmed.ncbi.nlm.nih.gov/19110211/)
rs12049330 — Major depressive disorder (p = 6.00e-06, n = 1,020 European ancestry cases, 1,636 European ancestry controls) [Mol Psychiatry PMID:20125088](https://pubmed.ncbi.nlm.nih.gov/20125088/)
rs1128334 — Systemic lupus erythematosus (p = 2.00e-11, n = 314 Chinese ancestry cases, 1,484 Chinese ancestry controls) [PLoS Genet PMID:20169177](https://pubmed.ncbi.nlm.nih.gov/20169177/)

📖 View canonical wiki page →

Related Entities

SORL1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-sorl1
kg_node_id	SORL1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f85c2de189bf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-sorl1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

46

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SORL1 Gene

SORL1 Gene

Pathway Diagram

SORL1 Gene

Pathway Diagram

Overview

Molecular Function

Protein Structure

Role in APP Processing

Retromer Function

Genetic Evidence for AD Risk

GWAS Associations

Rare Variants

Population-Specific Effects

Disease Mechanisms

Endosomal Trafficking Defects

Interaction with APOE

Glucose Metabolism

Expression Pattern

Brain Expression

Cellular Localization

Cell Type Specificity

Allen Brain Atlas Data

Gene Expression

Single-Cell Expression

Brain Region Expression Levels

External Resources

Therapeutic Implications

Targeting SORL1 Pathways

Retromer Stabilization

Challenges

Biomarker Potential

CSF Biomarkers

Imaging Biomarkers

Interaction Network

Comparison with Other AD Genes

Key Publications

See Also

External Links

Brain Atlas Resources

Epigenetic Regulation

DNA Methylation

Histone Modifications

Non-Coding RNAs

Animal Models

Knockout Mouse Models

Rescue Studies

Transgenic Models

Detailed Molecular Mechanisms

APP-SORL1 Binding Kinetics

Retromer Recruitment

Endosomal Sorting Complex

Therapeutic Approaches

Small Molecule Modulators

Gene Therapy

Protein-Based Therapies

Biomarker Development

Genetic Biomarkers

Expression Biomarkers

Functional Biomarkers

Sex-Specific Effects

Interaction with Other AD Genes

Future Research Directions

Clinical Implications

Diagnostic Applications

Therapeutic Development

Challenges and Considerations

References

Pathway Diagram

GWAS Evidence

💬 Discussion